Chlamydophila pneumoniae: From proteomics to arteriosclerosis;Chlamydophila pneumoniae: Desde su proteómica hasta la arteriosclerosis

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 26, Issue 10, 2008, Pages 629-637

  Villegas, Enrique ^a   Sorlózano, Antonio ^a   Camacho, Ana ^b   Gutiérrez, José ^a,c  

^a UNIVERSITY OF GRANADA   (Spain)

^b VIRCELL S L   (Spain)

^c UNIVERSITY OF GRANADA   (Spain)

Author keywords

Atherosclerosis; Chlamydophila pneumoniae; Proteomics

Indexed keywords

HEAT SHOCK PROTEIN 60; OUTER MEMBRANE PROTEIN;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; HUMAN; LIFE CYCLE; PNEUMONIA; REVIEW; RISK FACTOR; UPPER RESPIRATORY TRACT INFECTION;

ANIMALS; ANTIGENS, BACTERIAL; ARTERIOSCLEROSIS; BACTERIAL PROTEINS; CHLAMYDIALES; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; ENDOTHELIUM, VASCULAR; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KYNURENINE; LIPOPROTEINS, LDL; MACROPHAGES; MODELS, BIOLOGICAL; PNEUMONIA, BACTERIAL; PROTEOMICS; RABBITS; VASCULITIS;

EID: 58149470570     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(08)75279-0     Document Type: Review

References (66)

1. Everett KD, Bush RM, Andersen AA. Emended description of the order Chlamydiales, proposal of Parachlamydiaceae fam. nov. and Simkaniaceae fam. nov., each containing one monotypic genus, revised taxonomy of the family Chlamydiaceae, including a new genus and five new species, and standards for the identification of organisms. Int J Syst Bacteriol. 1999;49:415-40.
2. Kuo CC, Chen HH, Wang SP, Grayston JT. Identification of a new group of Chlamydia psittaci strains called TWAR. J Clin Microbiol. 1986;24:1034-7.
3. Kuo CC, Chi EY, Grayston JT. Ultrastructural study of entry of Chlamydia strain TWAR into HeLa cells. Infect Immun. 1988;56:1668-72.
4. Stratton WC, Mitchel WM. The pathogenesis of Systemic Chlamydial infections: theoretical considerations of host cell energy depletion and its metabolic consequences. AIDIEX. 1997;16:33-40.
5. Beatty WL, Belanger TA, Desai AA, Morrison RP, Byrne GI. Tryptophan depletion as a mechanism of gamma interferon-mediated chlamydial persistence. Infect Immun. 1994;62:3705-11.
6. Stratton WC. The role of Chlamydia in connective tissue diseases. AIDIEX. 1998;17:9-16.
7. Geisler WM, Suchland RJ, Rockey DD, Stamm WE. Epidemiology and clinical manifestations of unique Chlamydia trachomatis isolates that occupy nonfusogenic inclusions. J Infect Dis. 2001;184:879-84.
8. Montigiani S, Falugi F, Scarselli M, Finco O, Petracca R, Galli G, et al. Genomic approach for analysis of surface proteins in Chlamydia pneumoniae. Infect Immun. 2002;70:368-79.
9. Campbell S, Richmond SJ, Yates PS, Storey CC. Lipopolysaccharide in cells infected by Chlamydia trachomatis. Microbiology. 1994;140:1995-2002.
10. Peterson EM, de la Maza LM, Brade L, Brade H. Characterization of a neutralizing monoclonal antibody directed at the lipopolysaccharide of Chlamydia pneumoniae. Infect Immun. 1998;66:3848-55.
11. Birkelund S, Lundemose AG, Christiansen G. Immunoelectron microscopy of lipopolysaccharide in Chlamydia trachomatis. Infect Immun. 1989;57:3250-3.
12. Bavoil P, Ohlin A, Schachter J. Role of disulfide bonding in outer membrane structure and permeability in Chlamydia trachomatis. Infect Immun. 1984;44:479-85.
13. Wyllie S, Ashley RH, Longbottom D, Herring AJ. The major outer membrane protein of Chlamydia psittaci functions as a porin-like ion channel. Infect Immun. 1998;66:5202-7.
14. Christiansen G, Ostergaard L, Birkelund S. Molecular biology of the Chlamydia pneumoniae surface. Scand J Infect Dis Suppl. 1997;104:5-10.
15. Puolakkainen M, Parker J, Kuo CC. Characterization of a Chlamydia pneumoniae epitope recognized by species specific monoclonal antibodies. En: Orfila J, Byrne GL, Cherneskey A, Grayston JT, Jones JP, Ridgway GL, et al, editors. Chlamydial infections. Bologna: Società Editrice Esculapio; 1994. p. 185-8.
16. Newhall WJ. Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of Chlamydia trachomatis. Infect Immun. 1987;55:162-8.
17. Everett KD, Desiderio DM, Hatch TP. Characterization of lipoprotein EnvA in Chlamydia psittaci 6BC. J Bacteriol. 1994;176:6082-7.
18. Hatch TP, Allan I, Pearce JH. Structural and polypeptide differences between envelopes of infective and reproductive life cycle forms of Chlamydia spp. J Bacteriol. 1984;157:13-20.
19. Hatch TP. Disulfide cross-linked envelope proteins: the functional equivalent of peptidoglycan in chlamydiae? J Bacteriol. 1996;178:1-5.
20. Lindquist EA, Stephens RS. Transcriptional activity of a sequence variable protein family in Chlamydia trachomatis. En: Stephens RS, Byrne GI, Christiansen G, Clarke IN, Grayston JT, Rank RG, et al, editors. Chlamydial infections. Proceedings of the Ninth International Symposium on Human Chlamydial Infections. San Francisco, EEUU: International Chlamydia Symposium; 1998. p. 259-62.
21. Grimwood J, Olinger L, Stephens RS. Expression of Chlamydia pneumoniae polymorphic membrane protein family genes. Infect Immun. 2001;69:2383-9.
22. Vandahl BB, Pedersen AS, Gevaert K, Holm A, Vandekerckhove J, Christiansen G, et al. The expression, processing and localization of polymorphic membrane proteins in Chlamydia pneumoniae strain CWL029. BMC Microbiol. 2002;2:36.
23. Rockey DD, Viratyosin W, Bannantine JP, Suchland RJ, Stamm WE. Diversity within inc genes of clinical Chlamydia trachomatis variant isolates that occupy non-fusogenic inclusions. Microbiology. 2002;148:2497-505.
24. Toh H, Miura K, Shirai M, Hattori M. In silico inference of inclusion membrane protein family in obligate intracellular parasites chlamydiae. DNA Res. 2003;10:9-17.
25. Domeika M, Domeika K, Paavonen J, Mardh PA, Witkin SS. Humoral immune response to conserved epitopes of Chlamydia trachomatis and human 60-kDa heat-shock protein in women with pelvic inflammatory disease. J Infect Dis. 1998;177:714-9.
26. Lamb DJ, El-Sankary W, Ferns GA. Molecular mimicry in atherosclerosis: a role for heat shock proteins in immunisation. Atherosclerosis. 2003;167:177-85.
27. Taylor HR, Maclean IW, Brunham RC, Pal S, Whittum-Hudson J. Chlamydial heat shock proteins and trachoma. Infect Immun. 1990;58:3061-3.
28. Fong IW, Chiu B, Viira E, Tucker W, Wood H, Peeling RW. Chlamydial heat-shock protein-60 antibody and correlation with Chlamydia pneumoniae in atherosclerotic plaques. J Infect Dis. 2002;186:1469-73.
29. Hirono S, Dibrov E, Hurtado C, Kostenuk A, Ducas R, Pierce GN. Chlamydia pneumoniae stimulates proliferation of vascular smooth muscle cells through induction of endogenous heat shock protein 60. Circ Res. 2003;93:710-6.
30. Hueck CJ. Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev. 1998;62:379-433.
31. Subtil A, Parsot C, Dautry-Varsat A. Secretion of predicted Inc proteins of Chlamydia pneumoniae by a heterologous type III machinery. Mol Microbiol. 2001;39:792-800.
32. Vandahl BB, Birkelund S, Demol H, Hoorelbeke B, Christiansen G, Vandekerckhove J, et al. Proteome analysis of the Chlamydia pneumoniae elementary body. Electrophoresis. 2001;22:1204-23.
33. Fontan PA, Pancholi V, Nociari MM, Fischetti VA. Antibodies to streptococcal surface enolase react with human alpha-enolase: implications in post-streptococcal sequelae. J Infect Dis. 2000;182:1712-21.
34. Matsumoto A, Manire GP. Electron microscopic observations on the effects of penicillin on the morphology of Chlamydia psittaci. J Bacteriol. 1970;101:278-85.
35. Stephens RS, Kalman S, Lammel C, Fan J, Marathe R, Aravind L, et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science. 1998;282:754-9.
36. Holtje JV, Fiedler W, Rotering H, Walderich B, van Duin J. Lysis induction of Escherichia coli by the cloned lysis protein of the phage MS2 depends on the presence of osmoregulatory membrane-derived oligosaccharides. J Biol Chem. 1988;263:3539-41.
37. Rockey DD, Matsumoto A. The chlamydial developmental cycle. En: Brun YV, Shimkets LJ, editors. Prokaryotic development. Washington: Blackwell Publishing; 1999. p. 403-25.
38. Kumar S, Hammerschlag MR. Acute respiratory infection due to Chlamydia pneumoniae: current status of diagnostic methods. Clin Infect Dis. 2007;44:568-76.
39. Braun J, Laitko S, Treharne J, Eggens U, Wu P, Distler A, et al. Chlamydia pneumoniae; a new causative agent of reactive arthritis and undifferentiated oligoarthritis. Ann Rheum Dis. 1994;53:100-5.
40. Malinverni R, Kuo CC, Campbell LA, Grayston JT. Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone. J Infect Dis. 1995;172:593-4.
41. Carlin JM, Weller JB. Potentiation of interferon-mediated inhibition of Chlamydia infection by interleukin-1 in human macrophage cultures. Infect Immun. 1995;63:1870-5.
42. Thom DH, Grayston JT, Campbell LA, Kuo CC, Diwan VK, Wang SP. Respiratory infection with Chlamydia pneumoniae in middle-aged and older adult outpatients. Eur J Clin Microbiol Infect Dis. 1994;13:785-92.
43. Kishimoto T, Kimura M, Kubota Y. An outbreak of Chlamydia pneumoniae infection in households and schools. En: Orfila J, Byrne GL, Cherneskey A, Grayston JT, Jones JP, Ridgway GL, et al, editors. Chlamydial infections. Bologna: Società Editrice Esculapio; 1994. p. 465-8.
44. Moazed TC, Grayston JT, Campbell LA. A rabbit model of Chlamydia pneumoniae infection. En: Abstracts of the 94th General Meeting of the American Society for Microbiology. Washington: American Society for Microbiology; 1994; Abstr. B-214. p. 66.
45. Montes M, Cilla G, Alcorta M, Perez-Trallero E. High prevalence of Chlamydia pneumoniae infection in children and young adults in Spain. Pediatr Infect Dis J. 1992;11:972-3.
46. Hashigucci K, Ogawa H, Suzuki T, Kazuyama Y. Isolation of Chlamydia pneumoniae from the maxillary sinus of a patient with purulent sinusitis. Clin Infect Dis. 1992;15:570-1.
47. Ogawa H, Hashiguchi K, Kazuyama Y. Recovery of Chlamydia pneumoniae, in six patients with otitis media with effusion. J Laryngol Otol. 1992;106:490-2.
48. Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, et al. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis. 1992;14:178-82.
49. Gutiérrez J, Linares J, Camacho A, Palanca M, Maroto C, Ros E, et al. Descripción de inmunógenos de Chlamydia pneumoniae reconocidos por el suero de sujetos con enfermedad arterial periférica. Med Clin (Barc). 2006;126:721-7.
50. Kuo CC, Gown AM, Benditt EP, Grayston JT. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain. Arterioscler Thromb. 1993;13:1501-4.
51. Kuo CC, Shor A, Campbell LA, Fukushi H, Patton DL, Grayston JT. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries. J Infect Dis. 1993;167:841-9.
52. Grayston JT, Kuo CC, Coulson AS, Campbell LA, Lawrence RD, Lee MJ. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery. Circulation. 1995;92:3397-400.
53. Fong IW, Chiu B, Viira E, Fong MW, Jang D, Mahony J. Rabbit model for Chlamydia pneumoniae infection. J Clin Microbiol. 1997;35:48-52.
54. Kalayoglu M, Byrne G. Induction of macrophage foam cell formation by Chlamydia pneumoniae. J Infect Dis. 1998;177:725-9.
55. Ross R. Atherosclerosis. An inflammatory disease. N Engl J Med. 1999;340:115-26.
56. Gutiérrez J, Linares-Palomino J, Rodríguez M, Maroto MC. Chlamydia pneumoniae y su relación con la arteriosclerosis humana. Rev Invest Clin. 2000;52:482-6.
57. Fryer RH, Schwobe EP, Woods ML, Rodgers GM. Chlamydia species infect human vascular endothelial cells and induce procoagulant activity. J Investig Med. 1997;45:168-74.
58. Summersgill JT, Sahney NN, Gaydos CA, Quinn TC, Ramirez JA. Inhibition of Chlamydia pneumoniae growth in HEp-2 cells pretreated with gamma interferon and tumor necrosis factor alpha. Infect Immun. 1995;63:2801-3.
59. Helme S, Juvonen T, Laurila A, Juvonen J, Mosotin M, Saikku P, Surcel HM. Chlamydia pneumoniae reactive T lymphocytes in the walls of abdominal aortic aneurysms. Eur J Clin Invest. 1999;29:546-52.
60. Sakash JB, Byrne GI, Lichtman A, Libby P. Cytokines induce indoleamine 2,3-dioxygenase expression in human atheroma-associated cells: implications for persistent Chlamydophila pneumoniae infection. Infect Immun. 2002;7:3959-61.
61. Kane CD, Vena RM, Ouellette SP, Byrne GI. Intracellular tryptophan pool sizes may account for differences in gamma interferon-mediated inhibition and persistence of chlamydial growth in polarized and nonpolarized cells. Infect Immun. 1999;67:1666-71.
62. Kol A, Bourcier T, Lichtman AH, Libby P. Chlamydial and human heat shock protein 60s activate human vascular endothelium, smooth muscle cells, and macrophages. J Clin Invest. 1999;103:571-7.
63. Wyrick PB, Knight ST, Paul TR, Rank RG, Barbier CS. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis. J Infect Dis. 1999;179:954-66.
64. Gutiérrez J, de Dios Luna J, Linares J, del Rosario Montes M, Quesada E, Rojas A, et al. Relationship between peripheral arterial occlusive disease (PAOD) and chronic Chlamydophila (Chlamydia) pneumoniae infection: a meta-analysis. Thromb Haemost. 2005;93:1153-60.
65. Gois J, Higuchi M, Reis M, Diament J, Sousa J, Ramires J, Oliveira S. Infectious agents, inflammation, and growth factors: how do they interact in the progression or stabilization of mild human atherosclerotic lesions? Ann Vasc Surg. 2006;20:638-45.
66. Ameriso SF, Ruiz A, Pérez M. Infección, inflamación e ictus cerebral. Rev Esp Cardiol. 2004;4:7-12.